Our findings, combined with prior studies, support close monitoring with prompt antiviral initiation upon HBsAg reverse seroconversion as a viable alternative to prophylactic antiviral therapy in HBsAg-negative, anti-HBc-positive patients receiving anti-CD20 lymphoma-based chemotherapy. Here, KRT88P is linked to lymphoma.